DNA damage response mutations enhance the antitumor efficacy of ATR and PARP inhibitors in cholangiocarcinoma cell lines
Issued Date
2025-03-01
Resource Type
ISSN
17921074
eISSN
17921082
Scopus ID
2-s2.0-85215443287
Journal Title
Oncology Letters
Volume
29
Issue
3
Rights Holder(s)
SCOPUS
Bibliographic Citation
Oncology Letters Vol.29 No.3 (2025)
Suggested Citation
Lerksuthirat T., Prasopporn S., Wikiniyadhanee R., Chitphuk S., Stitchantrakul W., Owneium P., Jirawatnotai S., Dejsuphong D. DNA damage response mutations enhance the antitumor efficacy of ATR and PARP inhibitors in cholangiocarcinoma cell lines. Oncology Letters Vol.29 No.3 (2025). doi:10.3892/ol.2025.14874 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/103033
Title
DNA damage response mutations enhance the antitumor efficacy of ATR and PARP inhibitors in cholangiocarcinoma cell lines
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
Cholangiocarcinoma (CCA) is a biliary tract carci‑ noma that is challenging to treat due to its heterogeneity and limited treatment options. Genetic alterations in DNA damage response (DDR) pathways and homologous recombination (HR) defects are common in CCA. This has prompted interest in the use of ataxia telangiectasia and Rad3‑related protein (ATR) and poly(ADP‑ribose) polymerase (PARP) inhibitors to treat CCA. The present study investigated the impact of an ATR inhibitor and various PARP inhibitors, individually and in combination, on CCA cell lines with different DDR muta‑ tion profiles. DDR gene alterations in these cell lines were analyzed, and the responses of the cells to treatment with the PARP inhibitors olaparib, veliparib and talazoparib and/or the ATR inhibitor AZD6738 were evaluated. Assessments focused on cellular viability, clonogenic survival and the combination index, alongside changes in DNA damage assessed via the formation of micronuclei and γ‑H2A histone family member X foci. The results revealed that the CCA cell lines with more DDR mutations exhibited greater sensitivity to single and combination treatments. Talazoparib was found to be the most potent PARP inhibitor in the CCA cell lines. The combina‑ tion of AZD6738 and talazoparib demonstrated varying synergistic effects depending on the genetic background of the CCA cells, with greater efficacy in the cell lines less sensitive to single drug treatments. Mechanistically, this combination promoted the accumulation of DNA damage, including DNA double‑strand breaks. Overall, the study underscores the importance of HR in CCA. It reveals an association between the extent of DDR mutations and the response to AZD6738 and PARP inhibitors in CCA, both as single agents and in combination. These findings highlight that the number of mutated genes influences variability in the drug response.